# A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

> **NCT00595101** · PHASE2 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 117 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** PF-03187207
- **DRUG:** Latanoprost 0.005%
- **DRUG:** PF-03187207 Vehicle
- **DRUG:** Latanoprost Vehicle

## Key facts

- **NCT ID:** NCT00595101
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2020-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00595101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00595101, "A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00595101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*